Your email has been successfully added to our mailing list.

×
-0.167235494880546 -0.167235494880546 -0.143344709897611 -0.143344709897611 -0.112621160409556 -0.0443686006825939 -0.00682593856655288 -0.00682593856655288
Stock impact report

Opiant Pharmaceuticals Announces Top-line Results from Phase 2 Clinical Trial of OPNT001 for Treatment of Bulimia Nervosa

Opiant Pharmaceuticals, Inc. (OPNT) 
Last opiant pharmaceuticals, inc. earnings: 3/4 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.opiant.com/investor-overview
Company Research Source: GlobeNewswire
-Study did not meet primary endpoint- -Company discontinuing development of OPNT001 for treatment of Bulimia Nervosa- -Focus remains on advancing lead product candidate, OPNT003, for treatment of opioid overdose, and other promising addiction and drug overdose-related product candidates- SANTA MONICA, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced that its Phase 2 clinical trial evaluating OPNT001, a naloxone nasal spray for the treatment of bulimia nervosa (BN), did not meet the primary endpoint of reducing the number of binging days from baseline to week 8. Key secondary efficacy endpoints were also not met.   “Based on these results, Opiant will not allocate further  resources to the development of OPNT001 for the treatment of BN, allowing us to invest more in our pipeline. The company’s focus for 2019 remains on conducting the pivot Show less Read more
Impact Snapshot
Event Time:
OPNT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for OPNT alerts
Opt-in for
OPNT alerts

from News Quantified
Opt-in for
OPNT alerts

from News Quantified